Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA

Journal of Clinical Pathology

Volumn 66, Issue 10, 2013, Pages 854-861

  Henderson, Douglas W ^a,b   Reid, Glen ^c   Kao, Steven C ^c   Van Zandwijk, Nico ^c   Klebe, Sonja ^a,b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Asbestos Diseases Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 1; BIOLOGICAL MARKER; BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; FIBROBLAST GROWTH FACTOR 2; MICRORNA; MICRORNA 126; MICRORNA 141; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 31; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S 100; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; AREA UNDER THE CURVE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; COLONY FORMING UNIT; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INDEPENDENT VARIABLE; LUNG BIOPSY; LYMPHOCYTE; LYMPHOCYTE COUNT; MALIGNANT MESOTHELIOMA; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PLEURA EFFUSION; PLEURA TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RNA DEGRADATION; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA; THROMBOCYTOSIS; TUMOR GROWTH; UPREGULATION;

3-D RECONSTRUCTION; ACID PHOSPHATONE; ADENOVIRUS;

AQUAPORIN 1; DIAGNOSIS, DIFFERENTIAL; HUMANS; MESOTHELIOMA; MICRORNAS; MUTATION; PLEURA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; SARCOMA, SYNOVIAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84884985815     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201609     Document Type: Review

References (128)

1. Henderson DW, Shilkin KB, Whitaker D, et al. The pathology of mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D. eds. Malignant mesothelioma. New York: Hemisphere, 1992.:69-139.
2. Churg A. Neoplastic asbestos-induced disease. In: Churg A, Green FHY. eds. Pathology of occupational lung disease. 2nd edn. Baltimore: Williams & Wilkins, 1998.:339-91.
3. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris C. eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004:128-36.
4. Hammar SP, Henderson DW, Klebe S, et al. Neoplasms of the pleura. In: Tomashefski JF Jr. ed. Dail and Hammar's pulmonary pathology. 3rd edn. Vol 2. New York: Springer, 2008:558-734.
5. Brambilla E, Cagle PT, Churg AM, et al. International mesothelioma panel. In: Galateau-Sallé F. ed. Pathology of malignant mesothelioma. London: Springer, 2006.
6. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 2010;23:470-9.
7. Nascimento AG, Keeney GL, Fletcher CDM. Deciduoid peritoneal mesothelioma: an unusual phenotype affecting young females. Am J Surg Pathol 1994.;18:439-45. (Pubitemid 24134084)
8. Ordonez NG. Epithelioid mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol 2000;24:816-23. (Pubitemid 30366268)
9. Shanks JH, Harris M, Banerjee SS, et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol 2000;24:285-94. (Pubitemid 30078718)
10. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology 1992;20:47-51.
11. Henderson DW. Pleomorphic malignant mesothelioma. Histopathology 2002;41 (Suppl. 2):149-54.
12. Kadota K, Suzuki K, Sima CS, et al. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011.;6:896-904.
13. Ordonez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol 2012.;25:1011-22.
14. Henderson DW, Attwood HD, Constance TJ, et al. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988;12:367-84.
15. Henderson DW, Comin CE, Hammar SP, et al. Malignant mesothelioma of the pleura: current surgical pathology. In: Corrin B. ed. Pathology of lung tumors. New York: Churchill Livingstone, 1997:241-80.
16. Khalidi HS, Medeiros LJ, Battifora H. Lymphohistiocytoid mesothelioma: an often misdiagnosed variant of sarcomatoid mesothelioma. Am J Clin Pathol 2000.;113:649-54. (Pubitemid 33044304)
17. Yao DX, Shia J, Erlandson RA, et al. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct Pathol 2004;28:213-28. (Pubitemid 39490452)
18. Galateau-Sallé F, Attanoos R, Gibbs AR, et al. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases. Am J Surg Pathol 2007.;31:711-16. (Pubitemid 46684210)
19. Kawai T, Hiroi S, Nakanishi K, et al. Lymphohistiocytoid mesothelioma of the pleura. Pathol Int 2010;60:566-74.
20. Ouazzani A, Rondelet B, Sokolow Y, et al. Localized malignant lymphohistiocytoid pleural mesothelioma. Acta Chir Belg 2011;111:38-43.
21. Kannerstein M, Churg J. Desmoplastic diffuse malignant mesothelioma. In: Fenoglio CM, Wolff M. eds. Progress in surgical pathology. New York: Masson, 1980.:19-29.
22. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol 1992;45:295-8.
23. Mangano WE, Cagle PT, Churg A, et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 1998;110:191-9. (Pubitemid 28357658)
24. Husain AN, Colby T, Ordóñez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013.;137:647-67.
25. Henderson DW, Shilkin KB, Whitaker D, et al. Unusual histological types and anatomic sites of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D. eds. Malignant mesothelioma. New York: Hemisphere, 1992:140-66.
26. Churg A, Galateau-Sallé F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2012;136:1217-26.
27. Churg A, Cagle P, Colby TV, et al. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol 2011;35:1823-9.
28. Machin T, Mashiyama ET, Henderson JAM, et al. Bony metastases in desmoplastic pleural mesothelioma. Thorax 1988;43:155-6. (Pubitemid 18045565)
29. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2:401-21. (Pubitemid 128654510)
30. Begueret H, Galateau-Sallé F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol 2005;29:339-46. (Pubitemid 40321969)
31. Hisaoka M, Hashimoto H, Iwamasa T, et al. Primary synovial sarcoma of the lung: report of two cases confirmed by molecular detection of SYT-SSX fusion gene transcripts. Histopathology 1999;34:205-10. (Pubitemid 29152008)
32. Witkin GB, Miettinen M, Rosai J. A biphasic tumor of the mediastinum with features of synovial sarcoma: a report of four cases. Am J Surg Pathol 1989.;13:490-9. (Pubitemid 19149611)
33. Nicholson AG, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases. Histopathology 1998;33:508-13. (Pubitemid 28563375)
34. Suster S, Moran CA. Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical and ultrastructural study of 15 cases. Am J Surg Pathol 2005;29:569-78. (Pubitemid 40577865)
35. Hartel PH, Fanburg-Smith JC, Frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol 2007;20:760-9. (Pubitemid 46933447)
36. Nicholson AG, Rigby M, Lincoln C, et al. Synovial sarcoma of the heart. Histopathology 1997;30:349-52. (Pubitemid 27168795)
37. McGilbray TT, Schulz TK. Clinical picture: primary cardiac synovial sarcoma. Lancet Oncol 2003;4:283. (Pubitemid 36592495)
38. Fujimoto K, Hashimoto S, Abe T, et al. Synovial sarcoma arising from the chest wall: MR imaging findings. Radiat Med 1997;15:411-14. (Pubitemid 28100518)
39. Gaertner E, Zeren EH, Fleming MV, et al. Biphasic synovial sarcomas arising in the pleural cavity: a clinicopathologic study of five cases. Am J Surg Pathol 1996.;20:36-45. (Pubitemid 26007708)
40. Aubry MC, Bridge JA, Wickert R, et al. Primary monophasic synovial sarcoma of the pleura: five cases confirmed by the presence of the SYT-SSX fusion transcript. Am J Surg Pathol 2001;25:776-81. (Pubitemid 32496867)
41. Cappello F, Barnes L. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis. Pathology 2001.;33:142-8. (Pubitemid 32453404)
42. Colwell AS, D'Cunha J, Vargas SO, et al. Synovial sarcoma of the pleura: a clinical and pathologic study of three cases. J Thorac Cardiovasc Surg 2002.;124:828-32. (Pubitemid 36025363)
43. Praet M, Forsyth R, Dhaene K, et al. Synovial sarcoma of the pleura: report of four cases. Histopathology 2002;41(Suppl. 2):147-9.
44. Powers A, Carbone M. Diagnosis of synovial sarcoma of the pleura and differentiation from malignant mesothelioma. In: Pass HI, Vogelzang NJ, Carbone M. eds. Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. New York: Springer, 2005:543-54.
45. Weinbreck N, Vignaud JM, Begueret H, et al. SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. Mod Pathol 2007;20:617-21. (Pubitemid 46788868)
46. Ordóñez NG, Mahfouz SM, Mackay B. Synovial sarcoma: an immunohistochemical and ultrastructural study. Hum Pathol 1990;21:733-49. (Pubitemid 20216815)
47. De Leeuw B, Balemans M, Olde Weghuis D, et al. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)( p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet 1995;4:1097-9.
48. Brett D, Whitehouse S, Antonson P, et al. The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 1997;6:1559-64. (Pubitemid 27397034)
49. dos Santos NR, de Bruijn DR, Balemans M, et al. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum Mol Genet 1997.;6:1549-58. (Pubitemid 27397033)
50. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14:2333-40.
51. Haldar M, Hancock JD, Coffin CM, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007;11:375-88. (Pubitemid 46518310)
52. Davis SR, Meltzer PS. Modeling synovial sarcoma: timing is everything. Cancer Cell 2007.;11:305-7. (Pubitemid 46518316)
53. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008;466:2156-67.
54. Frazier AA, Franks TJ, Pugatch RD, et al. From the archives of the AFIP: pleuropulmonary synovial sarcoma. Radiographics 2006;26:923-40. (Pubitemid 43824985)
55. Amary MF, Berisha F, Bernardi Fdel C, et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol 2007;20:482-96. (Pubitemid 46482372)
56. Stimmler LM, Sykes P, Snell L, et al. Molecular tools for diagnosis of synovial sarcomas: correlation of RT-PCR and FISH on paraffin embedded material. Pathology 2009;42:S84.
57. Tsuji S, Hisaoka M, Morimitsu Y, et al. Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Am J Pathol 1998;153:1807-12. (Pubitemid 28550668)
58. Teo A, Hemmings C, Miller R. Sarcomatoid localised mesothelioma mimicking intrapulmonary synovial sarcoma: a case report and review of the literature. Pathology 2010;42:182-4.
59. Klebe S, Mahar A, Henderson DW, et al. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol 2008;21:1084-94.
60. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 2013;45:116-26.
61. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
62. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012.;36:818-30.
63. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-13.
64. Wiesner T, Fried I, Ulz P, et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol 2012;30: e337-40.
65. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
66. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
67. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103:868-74.
68. Knepper MA. The aquaporin family of molecular water channels. Proc Natl Acad Sci U S A 1994;91:6255-8. (Pubitemid 24200638)
69. Verkman AS, Mitra AK. Structure and function of aquaporin water channels. Am J Physiol Renal Physiol 2000;278:F13-28. (Pubitemid 30106122)
70. Verkman AS. Aquaporins. Curr Biol 2013;23:R52-5.
71. Ishibashi K, Hara S, Kondo S. Aquaporin water channels in mammals. Clin Exp Nephrol 2009;13:107-17.
72. King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996;58:619-48. (Pubitemid 26106737)
73. Verkman AS. Physiological importance of aquaporin water channels. Ann Med 2002.;34:192-200. (Pubitemid 34804192)
74. Verkman AS, Matthay MA, Song Y. Aquaporin water channels and lung physiology. Am J Physiol Lung Cell Mol Physiol 2000;278:L867-79. (Pubitemid 30351041)
75. Borok Z, Verkman AS. Lung edema clearance: 20 years of progress: invited review: role of aquaporin water channels in fluid transport in lung and airways. J Appl Physiol 2002;93:2199-206. (Pubitemid 35379348)
76. King LS, Nielsen S, Agre P. Aquaporin-1 water channel protein in lung: ontogeny, steroid-induced expression, and distribution in rat. J Clin Invest 1996.;97:2183-91.
77. Jiang J, Hu J, Bai C. Role of aquaporin and sodium channel in pleural water movement. Respir Physiol Neurobiol 2003;139:83-8. (Pubitemid 37443625)
78. Jiang JJ, Bai CX, Hong QY, et al. Effect of aquaporin-1 deletion on pleural fluid transport. Acta Pharmacol Sin 2003;24:301-5.
79. Liang Q, Xu SR, Liu W, et al. Expressions of aquaporin-1 on peritonea in hepatic cirrhotic rats with ascites. Zhonghua Yi Xue Za Zhi 2005;85:1027-30. (Pubitemid 40590349)
80. Song Y, Yang B, Matthay MA, et al. Role of aquaporin water channels in pleural fluid dynamics. Am J Physiol Cell Physiol 2000;279:C1744-50.
81. Kao SC, Armstrong N, Condon B, et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer 2012;118:2952-61.
82. Klebe S, Henderson DW. Early stages of mesothelioma, screening and biomarkers. In: Tannapfel A. ed. Malignant mesothelioma. Berlin: Springer, 2011.:169-93.
83. Lopez-Campos JL, Sachez Silva R, Gomez-Izquierdo L, et al. Overexpression of aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas. Histol Histopathol 2011;26:451-9.
84. Jagirdar R, Solenov EI, Hatzoglou C, et al. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. Gene 2013.;517:99-105.
85. Endo M, Jain RK, Witwer B, et al. Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. Microvasc Res 1999.;58:89-98. (Pubitemid 29419934)
86. Oshio K, Binder DK, Liang Y, et al. Expression of the aquaporin-1 water channel in human glial tumors. Neurosurgery 2005;56:375-81; discussion-81.
87. Clapp C, Martinez de la Escalera G. Aquaporin-1: a novel promoter of tumor angiogenesis. Trends Endocrinol Metab 2006;17:1-2. (Pubitemid 43031376)
88. Hoque MO, Soria JC, Woo J, et al. Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol 2006;168:1345-53.
89. Verkman AS, Hara-Chikuma M, Papadopoulos MC. Aquaporins: new players in cancer biology. J Mol Med (Berl) 2008;86:523-9.
90. Saadoun S, Papadopoulos MC, Hara-Chikuma M, et al. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005.;434:786-92. (Pubitemid 44739524)
91. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 2006;20:1892-4.
92. Nicchia GP, Stigliano C, Sparaneo A, et al. Inhibition of aquaporin-1 dependent angiogenesis impairs tumour growth in a mouse model of melanoma. J Mol Med (Berl) 2013;91:613-23.
93. Yool AJ, Brokl OH, Pannabecker TL, et al. Tetraethylammonium block of water flux in Aquaporin-1 channels expressed in kidney thin limbs of Henle's loop and a kidney-derived cell line. BMC Physiol 2002;2:4.
94. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma: a miRNA microarray analysis. Genes Chromosomes Cancer 2009;48:615-23.
95. Busacca S, Germano S, De Cecco L, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010;42:312-19.
96. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010;70:1916-24.
97. Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010;285:22809-17.
98. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010;12:771-9.
99. Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010.;127:2859-69.
100. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011.;80:193-208.
101. Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 2011.;6:e18232.
102. Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:1184-91.
103. Neumann V, Gunthe S, Muller KM, et al. Malignant mesothelioma: German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001.;74:383-95. (Pubitemid 32780717)
104. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525-30.
105. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
106. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-202. (Pubitemid 47244366)
107. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31. (Pubitemid 28130949)
108. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52. (Pubitemid 28041592)
109. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
110. Symanowski J, Rusthoven J, Nguyen B, et al. Multiple regression anaysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003.;22-647, abstr 2602.
111. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007;25:5770-6.
112. Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999.;189:72-8. (Pubitemid 29406822)
113. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003;124:1916-23. (Pubitemid 37433592)
114. Burgers JA, Damhuis RA. Prognostic factors in malignant mesothelioma. Lung Cancer 2004;45(Suppl. 1):S49-54. (Pubitemid 38917114)
115. Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382-7. (Pubitemid 41698667)
116. Kokturk N, Firat P, Akay H, et al. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005;50:189-98. (Pubitemid 41427894)
117. Kumar P, Kratzke RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 2005;49(Suppl. 1):S53-60. (Pubitemid 40798847)
118. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008.;33:502-6.
119. Brauer C, Baandrup U, Jacobsen P, et al. Screening for asbestos-related conditions. Ugeskr Laeger 2009;171:433-6.
120. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007.;13:5076-81. (Pubitemid 47502073)
121. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95:598-605. (Pubitemid 36553506)
122. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005.;11:4406-14. (Pubitemid 40825631)
123. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009.;101:678-86.
124. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-13.
125. Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 2011.;6:1923-9.
126. Cedres S, Montero MA, Martinez P, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012;77:192-8.
127. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012;7:587-94.
128. Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer 2013.;14:70-7.